In the UK, the Medicines and Health Products Regulatory Board recommended that other vaccines approved for emergency use in the country should be made instead of the Oxford-AstraZeneca’s new type of coronavirus vaccine, which is considered to cause more blood clotting in those under the age of 40.
In the statement, it was noted that MHRA recommended that young people under 40 should be given other vaccines approved for use in the country instead of the Oxford-AstraZeneca vaccine, on the grounds that clotting rates are higher in young people.
In the statement, which pointed out that Covid-19 vaccines significantly reduce the risk of death, severe disease and transmission, it was stated that the benefit of the Oxford-AstraZeneca vaccine is more than its risk.
THE NUMBER OF THE VACCINATED PEOPLE APPROACHED TO 35 MILLION
In the statement, it was reported that in the country where the number of people who had the first dose of Covid-19 vaccine reached 34 million 934 thousand 171, it was estimated that more than 10 thousand people were prevented from losing their lives with the vaccination program that started on December 8, 2020.
Prof Wei Shen Lim, Chairman of the Joint Vaccination and Immunization Committee (JCVI), whose evaluations were included in the statement, stated that their priority is the safety of vaccines.
“WE RECOMMEND AN ALTERNATIVE VACCINE”
Lim said, “Since Covid-19 rates continue to be controlled, we recommend alternative Covid-19 vaccines instead of the Oxford-AstraZeneca vaccine if it does not cause delay in the progress of the vaccination program for those aged 18-39 who do not have chronic health problems.” used the expressions.
MHRA announced that 79 blood clotting cases were reported between 8 December 2020 – 31 March 2021, and 19 of these people died.
In the country, on April 7, it was announced that Pfizer or Moderna would be vaccinated instead of the Oxford-AstraZeneca vaccine on the grounds that it causes blood clotting in those under 30.
Some European countries have suspended or limited the use of the vaccine on the grounds that it causes blood clotting.
MHRA approved the emergency use of the Oxford-AstraZeneca vaccine, as well as the Pfizer-BioNTech and Moderna angles.